83-2272-57　［受注停止］KRIBIOLISA Tarlatamab ELISA 1 x 96 wells　KBI1769

特徴

• Description：ELISA for the detection of Tarlatamab in human serum and plasma.
• Lead time for this kit is 5 weeks.
• About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.
• Tarlatamab is an HLE BiTE immuno-oncology therapy designed to bind DLL3 on target cancer cells and CD3 on T cells, forming a cytolytic synapse inducing T cell activation and expansion and T cell-dependent killing of tumor cells.
• Delta-like ligand 3 （DLL3） is a Notch ligand that is upregulated and aberrantly expressed on the cell surface in most Small Cell Lung Cancer, making it a compelling therapeutic target.
• Phase I trials have shown promising results - tarlatamab was reasonably effective and had manageable levels of toxicity.